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Abstract
Malignant melanoma is the most aggressive form of skin
cancer and has been traditionally considered difficult to treat.
The worldwide incidence of melanoma has been increasing
faster than any other type of cancer. Early detection, sur-
gery, and adjuvant therapy enable improved outcomes;
nonetheless, the prognosis of metastatic melanoma remains
poor. Several therapies have been investigated for the
treatment of melanoma; however, current treatment options
for patients with metastatic disease are limited and non-
curative in the majority of cases. Photodynamic therapy
(PDT) has been proposed as a promising minimally invasive
therapeutic procedure that employs three essential elements
to induce cell death: a photosensitizer, light of a specific
wavelength, and molecular oxygen. However, classical PDT
has shown some drawbacks that limit its clinical application.
Inviewof this,the use ofnanotechnology has beenconsidered
since it provides many tools that can be applied to PDT to
circumvent these limitations and bring new perspectives for
the application of this therapy for different types of diseases.
On that ground, this review focuses on the potential use of
developing nanotechnologies ableto bring significant benefits
for anticancer PDT,aiming toreachhigherefficacyandsafety
for patients with malignant melanoma.
Keywords: photodynamic therapy; skin cancer; melanoma;
nanoparticles; nanotechnology
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T
he incidence of melanoma has been continuously
increasing over the past decades to the extent that
it is now reaching epidemic proportions in white
populations worldwide (1, 2). According to the latest
report by the World Health Organization, approximately
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(page number not for citation purpose)232,130 new cases of melanoma skin cancer occurred
globallyin2012(3).Moreover,thelatestAmericanCancer
Society report (2013) states that about 76,690 new
melanoma cases were to be diagnosed and about 9,480
people were expected to die of melanoma in 2013 (4).
Malignantmelanomaisthemostaggressiveformofskin
cancer and develops as a result of the combination of both
genetic and environmental factors (5, 6). This type of
cancer is generated by malignant phenotypes of the skin
melanocyte, a cell type that originates from the developing
neural crest and migrates to the skin, hair follicles, eyes,
andears(6).Intheskin,themelanocyteresidesinthebasal
layer of the epidermis surrounded by approximately 36
keratinocytes  a compartment referred to as the epidermal-
melanin unit (EMU). In the EMU, the melanocyte pro-
duces the pigment melanin via the enzymatic process of
melanogenesis in specialized intracellular organelles
called melanosomes (7). Presence of this cell-specific
organelle  the melanosome  and its associated product,
melanin pigment, set melanoma apart from all other types
of cancers. Thus, treatments targeting melanoma should
stronglyconsiderthemelanosometosuccessfullyfightthis
type of cancer (8).
Melanoma can be classified into three categories:
cutaneous melanoma (91.2%), ocular melanoma (5.3%),
and mucosal melanoma (1.3%) (9). Ocular melanoma,
also known as uveal melanoma or choroidal melanoma,
is the most common primary intraocular malignant
tumor (10). Mucosal melanoma can occur in any mucous
membrane of the body, including the nasal cavity and
accessory sinuses, oral cavity, anorectum, and others (11).
Cutaneous melanoma is the most common type, known
as a heterogeneous disease with many clinicopathologic
subtypes. Of these, the majority fits into four categories:
superficial spreading melanoma (SSM), nodular melanoma
(NM), lentigo maligna (LM), and acral lentiginous
melanoma (ALM), comprising 7075%, 2025%, 510%,
and 5% of cutaneous melanoma cases, respectively,
in White Caucasian populations (12). However, acral mela-
nomas represents the most prevalent histologic sub-
type in African, African American, Chinese, Taiwanese,
and mixed racial heritage populations (13). Besides
histopathological differences among these subtypes of
cutaneous melanoma, other clinical factors differentiate
them. LM begins as a tan macule that extends periph-
erally, with gradual uneven darkening over the course
of years and tends to be more common in older patients
with heavily sun-damaged skin. Unlike LM, SSM has
no preference for sun-damaged skin, being associated
with intermittent and sporadic sun exposure. The upper
back in both sexes and the legs in women are the most
common sites. There is a tendency to multicoloration, not
just with different shades of tan, but variations of black,
red, brown, blue, and white. ALM appears more com-
monly in the foot, demonstrates a junctional growth
pattern, indistinct margins, and over time, a vertical
growth phase develops and shows little association with
sun exposure. NM presents lesions that arise without
a clinically apparent radial growth phase, but usually
large atypical melanocytes can be found in the epider-
mis beyond the region of vertical growth. Tumors appear
primarily on sun-exposed areas of the head, neck, and
trunk, and may be smooth and dome-shaped, fungating,
friable, or ulcerated. Bleeding is usually a late sign (13, 14).
Melanomas are also classified in relation to melanin
content.Mosttypesofmelanomasaremelanotic,contain-
ing various degrees and types of pigmentation (melanin);
however, any clinical subtype of primary cutaneous
melanoma or metastatic melanoma may be amelanotic,
presenting the absence of pigmentation in the tumor.
Amelanotic melanoma represents 1.88.1% of all such
tumors (15).
Unfortunately, rapid increase in malignant melanoma
incidence has not been paralleled by the development
of better therapeutic options over the last decades (16).
Patients with early-stage, non-metastatic melanoma can be
treated by the surgical removal of the tumor, with high
survival rates. For instance, patients with removable mela-
noma were treated with chemosurgery, reaching a cure rate
of 9799.8% (17, 18). However, the scenery is quite
different for metastatic melanoma. Once melanoma has
developed into late-stage, metastatic disease, it is difficult
to treat, resulting in high mortality (1, 4, 19). Median
survival time of patients with unresectable melanoma,
depending on the patient’s performance status, as well as
location and number of metastases, is only about 28
months (19). Available treatments, such as chemotherapy,
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fect against metastatic melanoma, while causing serious
health-threatening effects related to the lackof specificity for
tumor cells (20, 21). In the case of patients with unresectable
melanoma under conventional treatments, a 3-year overall
survival rate of less than 15% is generally observed (1, 4).
Currently, the standard reference drug for chemother-
apy in patients with advanced melanoma is dacarbazine
(DTIC), the first-line treatment for patients with mela-
noma (22), showing response rates of 1525%, with
median response durations of 56 months, and less than
5% of complete responses (19). These grim outcomes are
due to problems frequently stated for dacarbazine, such
as its low chemical stability, rapid metabolization follow-
ing intravenous administration, melanoma resistance,
and negative adverse effects (23). Attempts to improve
the therapeutic index of dacarbazine with nanotechno-
logical tools have been described in literature (2426). In
these studies, better dacarbazine anticancer activity was
obtained when the drug was incorporated into nanofor-
mulations, attributing greater drug stability conferred by
nanostructures (2426) and to alleged size-dependent modi-
fication of drug pharmacokinetics (2426). However, to
the authors’ knowledge, so far there are no clinical studies
reporting the use of dacarbazine in nanoformulations.
Considering results obtained for melanoma patients
treated with dacarbazine, it becomes clear that improved
melanoma diagnosis methods and new treatments with
higher therapeutic indices are needed. Photodynamic
therapy (PDT) has been pointed out over the last years
as a candidate for improving melanoma treatment (27),
as well as other skin cancer types. At the same time, other
studies have additionally investigated as to whether some
of the tools available in PDT could also be of use for
melanoma diagnosis (28). However, PDT still presents a
series of limitations that interfere with its capacity to
efficiently treat cancer (2931).
Nanotechnology has recently been considered as a tool
to counter these drawbacks (3235). In general terms, the
application of nanotechnology in PDT aims to improve
water compatibility of hydrophobic drugs/photosensitizer
(PS), protect the drug from degradation, produce a
prolonged release of the drug, increase drug bioavail-
ability (35), increase tumor selectivity, and permit greater
penetration depths for the treatment of deep seated
tumors, thus increasing treatment efficacy and reducing
side effects (36). In view of these factors, the focus of this
review is to propose and discuss the potential use of
developing nanotechnologies able to bring important
benefits for anticancer PDT aiming to reach higher
efficacy and safety for melanoma theranostics.
Photodynamic therapy
PDT represents a promising minimally invasive thera-
peutic procedure that employs two individually non-
toxic components that are combined to induce a strong
oxidative stress in a biological target, intended for the
treatment of a variety of solid tumors and non-malignant
lesions(37,38).Oneofthecomponentsislightofaspecific
wavelength, while the other one is a photosensitizer  a
molecule that converts light energy into chemical poten-
tial. Once the PS absorbs light, it reaches a singlet excited
state and, eventually, it may reach, by intersystem cross-
ing, a relatively stable energetic state called the excited
triplet state. PS in its excited triplet state may then directly
react with different surrounding molecules  type I
photoreactions  or react with molecular oxygen  type II
photoreactions. As molecular oxygen is present in tumor
sites, type II photoreactions are of particular interest in
anticancer PDT. In type II photoreactions, PS promotes,
in the presence of molecular oxygen, the transition from
the triplet ground state (
3O2) to the singlet excited state
(
1O2) (34). These events are summarized in Fig. 1.
Inabiologicalmedium,
1O2promptlyreactswithseveral
surrounding biomolecules, such as proteins, lipids, and
nucleic acids (36). This oxidative damage to biomolecules
may lead to threebiological events that are highly relevant
Fig. 1. Diagram illustrating the main events leading to photoreactions of type I and II that ultimately may lead to oxidative cell
damage. PSphotosensitizer;
1PS*singlet excited state PS;
3PS*triplet excited state PS; hnphoton; ISCintersystem
crossing;
3O2triplet oxygen;
1O2singlet oxygen; Ssubstrates (biomolecules); Smodchemically modiﬁed biomolecules.
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(page number not for citation purpose)in anticancer PDT: 1) direct cancer cell death by necrosis,
apoptosis, or autophagy; 2) tumor ischemia following
PDT-induced vascular damage; and 3) activation of the
immune system against tumor antigens. Moreover, these
three biological mechanisms of PDTmay interact with the
mechanisms of other chemotherapeutic drugs, raising the
possibility of applying PDT along with other drugs in a
single anticancer therapy. For example, Castano et al.
showed that the combination of low-dose cyclophospha-
mide therapy and PDT, both known to activate and boost
theimmuneresponseagainsttumors,ledtotheelimination
of highly metastatic J774 sarcoma cells in a mouse model,
which was not observed when these two therapies were
applied isolated (39).
As the cytotoxic mechanism of PDT involves PS
activation by light of specific wavelength in order to
produce oxidative species, the phototoxic effects of PDT
and the safety of this procedure may be restricted to the
tumor site by simply focusing the light beam on the target
area. Thus, PDT represents a site-specific treatment trig-
gered by local light activation (40, 41). In the case of
the skin, since it is the tissue most probably exposed to sun
light or light emitted by other sources, the issue of skin
photosensitization is the most common negative effect
observed in PS, as reviewed elsewhere (40). These adverse
effectstonon-targetareasaregenerallyrelatedtoexposure
of these sites to non-therapeutic light, instead of being
related to the toxicity of the PS itself in the absence of
light (41). However, this side effect is not so therapy
limiting if compared to those elicited by other chemother-
apeutic drugs, mainly when the patient is properly advised
toavoid exposition tolight during theperiod oftreatment.
In the case of PS used in clinical practice, such as 5-
aminolevulinic acid (ALA), which is applied topically, and
methyl aminolevulinate (MAL) applied intravenously (i.e.
Phoscan and Photofrin), further specificity to cancer is
reached because these molecules are pro-drugs, and thus
need to be metabolized into active PS, protoporphyrin IX
(PpIX),beforelightisapplied.Ascancercellsaregenerally
more active in converting ALA and MAL to PpIX, they
concentratemorePpIXincomparisontonormalcells(42).
Other methods for increasingspecificityofPDTtotumors
were also described elsewhere (43). Nanotechnology may
increase the accumulation of PS in tumor tissue, as
described in this review.
Several studies have demonstrated PDT as a viable
treatment option against early-stage cancer such as
esophageal dysplasia (44), lung cancer (45), head and
neckcancer(4649), non-melanomaskincancer(50),anal
cancer (51), peritoneal ovarian cancer (52), and others.
PDT has also been successfully used as co-therapy in
late-stage cancer and also has been shown as clinically
effective for the treatment of non-cancerous skin lesions,
suchasrecalcitrantwarts,acnevulgaris,andpsoriasis(53).
Still,someobstaclesintheclinicaladoptionofPDTforthe
treatmentofcancerpersist(9,39).Inawaytocounterthese
problems, more recently, studies have reported the use of
PDT combined with other therapies, such as cryotherapy
(54) and carbon dioxide laser (55) for the treatment of
nodular basal cell carcinoma skin cancer, demonstrating
good efficacy and satisfactory cosmetic outcomes. Never-
theless, when it comes to the use of PDT against mela-
noma, some particularities of this type of cancer raise
important questions that need to be taken into account.
PDT for the treatment of melanoma
As previously discussed, PS activation by light in the
presence of molecular oxygen represents a crucial event
in PDT. Ideally, light used in PDT should be poorly
absorbed by biological tissues and strongly absorbed by
the PS. Biological tissues generally show low absorption
of light with wavelengths between 650 and 800 nm and,
therefore, this range is called the optical window of
biological tissues. In the case of cutaneous melanomas,
however, the scenery is different due to the presence of a
high content of melanin (56, 57).
Melanin is a skin photoprotectant that absorbs light
over the entire wavelength region used for PDT (400750
nm) (57), presenting stronger absorptions in the shorter
wavelengths of this spectral range (16) (Fig. 2). Hence,
melanin competes with PS for the light used in PDT.
Consequently, melanotic melanomas have commonly
presented a poor response to classical PDT. In order to
prove that melanin is in fact a major obstacle for PDT
treatment, several studies have compared experimental
results with pigmented (such as B16F1 and B16F10) and
depigmented cell lines (for instance, A375) (58, 59) or
normal melanoma cell lines with photobleached melanin
(57). These studies have reinforced that the lack of
pigmentation in melanomas decreases resistance to cell
death after PDT treatment (60).
A series of modifications and improvements applied on
classical PDT have led to better results for melanoma
treatment. Studies with PS absorbing in the far-red region
Fig. 2. Contribution of different compounds to the optical
density of biological tissues.
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obstacle for applying PDT against pigmented tumors,
such as B16 pigmented melanoma (61, 62). However, as
stated by Bechet and collaborators (32), the majority of
existent PS have not yet made it to clinical trials due to
factors such as poor selectivity in terms of target tissue
and healthy tissue, low extinction coefficients, absorption
spectra at relatively short wavelengths, and high accumu-
lation rates in the skin. Most PS that are commercially
available present specific beneficial characteristics, but so
far none of these incorporate all the properties of an ideal
PS, which should present: a stable composition, minimal
self-aggregation tendency, non-toxicity in the absence of
light exposure, photostability, quick clearance from the
body, and target specificity, among other characteristics
(32). Thus, as observed for different cancer treatments,
the use of nanotechnology as a tool for the treatment of
melanoma through PDT becomes a very promising
approach, since proper preparation and application of
these nanomaterials could satisfy all or at least most of
the requirements for an ideal photosensitizing agent.
Nanotechnology as a tool for improved
anticancer efficiency
Nanotechnology is related to the understanding and
control of matter at dimensions roughly in the range
of1100nm,ascaleatwhichuniquechemicalandphysical
properties of materials emerge, allowing to develop,
for instance, novel diagnostic and treatment modalities
(6367).
In the case of melanoma, a range of nanoparticle
formulations could be envisaged to act as carriers of con-
ventional chemotherapeutic drugs, such as dacarbazine,
paclitaxel, docetaxel, doxorubicin, cisplatin, vincristine,
and carboplatin (1, 68). More recently, in 2011, the U.S.
FoodandDrugAdministration(FDA)approvedZelboraf
(vemurafenib) and Yervoy (ipilimumab) (69), pharmaceu-
ticals that are poised to become the therapy of choice for
patients with previously untreated advanced melanoma
(70). Moreover, considering that approximately half of
melanomas that arise in the skin present a BRAF gene
mutation (71), the FDA approved in 2013 the use
of two new drugs, Tafinlar (dabrafenib) and Mekinist
(trametinib), for patients with unresectable melanoma
(72). Initially, in 2013 the FDA approved these drugs to
be used as single agents, not as a combination treatment
(72). Nonetheless, new information released in January of
2014 declared that the FDA now approves Mekinist
(trametinib) in combination with Tafinlar (dabrafenib) to
treatpatientswithadvancedmelanomathatisunresectable
or metastatic (late-stage) (73). Some of these chemother-
apeuticshavealreadybeennanoencapsulatedinliposomes,
dendrimers, polymersomes, carbon-based, inorganic, and
protein-basednanoparticles(22),whichmaybeusedinthe
future for the treatment of melanoma.
Generally, compared with conventional drug delivery
approaches, nanoparticle-mediated delivery of anticancer
chemotherapeutic drugs has been reported as a way to
improve pharmacokinetic properties of compounds. This
isattributabletobettertumoraccumulationbypassiveand
active targeting, sustained drug release, and prolonged
blood circulation times (1).
Nanotechnology applications for PDT
The use of nanotechnology has provided many tools
that can be applied to PDT, bringing new perspectives
for the application of this therapy for different types
of diseases, such as melanoma. For instance, lipid-based
nanoparticles (NPs) (36, 74), polymer-based NPs (75),
polyethylene glycol (PEG)-lipid micelles (76), silica-based
NPs (60, 77), gold NPs (7880), upconversion nanopar-
ticles (UCNPs) (81), iron oxide NPs (8284), nanocap-
sules (8587) and fullerenes (88, 89) have already been
applied in the treatment of melanoma in in vitro and
in vivo experimental models, showing interesting results
(Table 1).
According to Paszko and collaborators (34), most
current studies on nanotechnology for PDT are aimed
at either improving existing formulations of clinically
approved PS or are focused on the development of
targeted delivery vehicles. Application of nanotechnology
in PDT may also aim to improve the solubility of poorly
water-soluble drugs, protect the drug from degradation,
produce a prolonged release of the drug, and increase
drug bioavailability (35, 90). Other advantages presented
by nanoparticles include multidrug loading capacity,
facilitating combination therapy; and design of NPs to
have multiple functions, such as targeting to cancer cells
and at the same time permit image contrast (22).
Some of the main possibilities raised by nanotechnol-
ogy regarding necessary improvements for anticancer
PDT to reach higher efficacy and safety are discussed
in more details below.
Delivering the PS to its action site
As for other anticancer drug therapies, PDT efficacy and
safety can be improved by increasing the amount of drug
reaching the tumor site while decreasing its concentra-
tions in non-target tissues. The first experimental che-
motherapeutic drug incorporated in nanocarriers were
tested in the 1980s, when initial results already demon-
strated that better therapeutic indexes could be reached
for classical anticancer drugs by associating them with
nanostructured drug delivery systems (9193). Some
of these nanostructured systems are known to accumu-
late passively in some kinds of solid tumors due to the
enhanced permeation and retention (EPR) effect, which
is a consequence of defective microvasculature and lym-
phatic drainage observed in several solid tumors (34, 94).
Blood capillary vessels in tumor tissue may have fenestrae
Nanotechnology for PDT against melanoma
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(page number not for citation purpose)Table 1. Types of nanomaterials used with Photodynamic Therapy (PDT) for the treatment of melanoma in in vitro and in vivo experimental models. Beneﬁts and drawbacks
related to the application of each type of nanomaterial are also cited.
Nanomaterial
Photosensitizer (PS) incorporated into
the nanomaterial Benefits Drawbacks
Lipid-based NPs
Liposomes Liposomeschloroaluminum
phthalocyanine (74)
- Versatility
- PS protection
- Drug delivery
- Most extensively studied type of nanocarrier system
- Prevents PS aggregation
- Works with hydrophobic and hydrophilic PS (36)
- Permits the use of lower concentration of the PS and lower light doses than
those applied in current protocols (74)
- Short plasma half-life
- Opsonization by plasma proteins and reticulum
endothelial system (RES) (36)
Polymer-based NPs
Poly (lactic-co-glycolic
acid) (PLGA)
PLGAmeso
Tetraphenylporpholactol
(m-TPPPL) (75).
- Ability to deliver large amounts of PS to target area
- Flexibility toward surface modification for better efficiency
- Ability to prevent degradation in the living biological environment
- Possibility of being loaded with multiple components such as targeting ligands
and contrast agents (36)
- Easy to formulate
- Biodegradable
- Biocompatible
- Stable
- Non-phototoxic upon systemic administration
- Upon cellular internalization, the PS is released from the NP and becomes
highly phototoxic (36, 75)
- Tendency to be taken up by macrophages after
intravenous administration (36)
Polyethylene glycol
(PEG)-lipid
micelles
Meso-5,10,15,20-tetraphenyl-
21H,23H-porphine (TPP) (76).
- PEG prevents rapid uptake of the particles by RES (36)
- PEG-PE micelles allowed a 150-fold increase in the solubilization of TPP,
compared with the free drug (76)
Silica-based NPs
(SiNPs)
Silicon phthalocyanine 4 (Pc4) (60) - Large surface area and pore volume allow for high drug loading
- Tunable diffusional release of drug molecules from the highly ordered
mesoporous structure gives rise to a biogenic local concentration at the
targeted area, reducing the overall dosage and preventing any acute or chronic
complications
- Offer the ability to effectively protect the pharmaceutical cargoes from
premature release and the undesired degradation in harsh environments (77)
- A variety of precursors and methods are available for their syntheses, allowing
flexibility and thus numerous PDT drugs can be encapsulated
- SiNPs also have advantages as drug vectors; compatibility in biological
systems and are not subject to microbial attack (36)
- Offer the possibility to functionalize their surface with stimuli-responsive groups
for controlled release of various cargos (77)
- Encapsulation of Pc4 in silica NP improved the aqueous solubility, stability, and
delivery of the photodynamic drug, increased its photodynamic efficacy
compared to free Pc4 molecules (60)
- Factors such as surface area and size distribution,
chemical composition, surface structure, solubility,
shape, and aggregation are potentially toxic triggers (77)
Gold NPs - Improved targeting effect
- Small size permits enhanced permeation of tumor tissue and vasculature
- Chemical inertness
- Minimum toxicity
- Can serve both as diagnostic and therapeutic tools for cancer
- Toxicity in live human subjects; ultimate destination, and
possible pathways; and mechanisms for their
absorption, circulation, distribution, metabolism, and
excretion (79)
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Nanomaterial
Photosensitizer (PS) incorporated into
the nanomaterial Benefits Drawbacks
Shells of charged
biocompatible
polymers grafted on
gold nanospheres (80).
Zn(II)-phthalocyanine disulphide
(C11Pc) (78)
Dibromobenzene-based chromophore
(DBB) (80)
- Versatile surfaces
- Tunable sizes
- Unique optical properties
- Can be coated with PEG serving as drug delivery systems for PDT (stabilization
by steric repulsion and inhibition of colloid aggregation in physiological
conditions) (36, 79)
- PDT studies with the C11Pc-loaded amelanotic melanoma showed extensive
damage of the blood capillaries and the endothelial cells (78)
Upconversion
nanoparticles
(UCNs)
Mesoporous silicacoated
upconversion fluorescent
nanoparticles (UCNs) loaded with
merocyanine (MC540) and zinc (II)
phthalocyanine (ZnPc) (81)
- Monodispersibility
- Controllable size of less than 100 nm
- Noninvasive imaging of deep tissues
- Drug delivery
- Allows existing photosensitizers to overcome the limited penetration of their
activation light and potentially attain their full therapeutic potential (36)
- Unstable attachment and low attachment efficiency of
the photosensitizers to the UCNs when shells are not
used (36, 81)
Iron oxide
nanoparticles
(IONPs)
- Nanocomposite: IONSPs
fullerenesPEG
hematoporphyrin monomethyl ether
(82)
- Iron oxide magnetic core coated
with a biocompatible dextran shell
bearing polyaminated chlorin
p6 (83)
- Strong superparamagnetism and powerful photodynamic therapy capacity (83)
- Promising tool for the site-specific delivery of drugs and diagnostic agents by
an external magnetic field applied outside the body (36)
- Opsonization; particle aggregation; potential
disturbance in iron homeostasis; biodegradability;
biocompatibility (84)
Nanocapsules - Nanocapsules containing
chloroaluminum phthalocyanine
(ClAlPc) (85)
- Nanoencapsulation enables application of hydrophobic photosensitizers with
the use of both low sensitizer drug concentration and light dose (85)
- Polymeric shell protection against degradation factors like pH and light and
the reduction of tissue irritation due to the polymeric shell (86)
- When the drug or PS is entrapped, it has to be added
before or during the formulation process, and is thus
likely to be degraded (87)
Fullerenes - Fullerene is the actual PSi.e.
D-glucose residue pendant fullerene
(88)
- Potent agents in photodynamic therapy and magnetic imaging
- Excellent triplet sensitizers
- Capable of reacting with a wide range of biological targets and killing cancer
cells (89)
- Poor in terms of solubility in commonly used organic
solvents
- Insoluble in aqueous media (89)
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)of about 200 and 800 nm in diameter, much larger than
those observed in the microvasculature of normal tissues
(34, 94). Experiments showing the size-dependent accu-
mulation of particles in tumor tissues (95) demonstrate
that size matters in anticancer chemotherapy. Thus, by
using nanoparticles of an adequate size, it is possible to
increase PS concentration in tumor tissue while reducing
it in normal tissues (32, 78, 96, 97).
It is also possible to increase the accumulation of
drugs in tumors by means of active targeting strategies.
Molecules such as antibodies, cationic peptides, agonists
of membrane receptors, and others, can be attached to
the surface of drug-loaded nanoparticles, increasing
their affinity for tumor tissue (98100). This strategy was
already applied in drug delivery systems intended for PDT
application.Forinstance,biocompatibleblockco-polymer
micelles containing Pc4 PS were surface-modified with
epidermalgrowthfactorreceptor(EGFR)-targetingGE11
peptides for active targeting of EGFR-overexpressing
cancer cells. These micelles were incubated with epider-
moid carcinoma cells, later treated with PDT. Results
indicated that active targeting with EGFR accelerated
intracellular PSuptake,enhancing PDT-inducedcytotoxi-
city (97). Moreover, new conjugates consisting of nano-
bodies (NB) targeting the EGFR and a traceable PS were
studied. Results showed that these conjugates specifically
induced cell death of EGFR overexpressing cells in
low, nanomolar concentrations, while PS alone or NB
PS conjugates in the absence of light induced no toxicity
(101).
PDT efficiency was also demonstrated in folic-acid
conjugated graphene oxide loaded with chlorin e6 when
treatinghumanstomachcancerMGC803cells(102).Yoon
and collaborators (103) also tested chlorin e6 in tumor-
targeting hyaluronic acid nanoparticles (HANPs) used
as nanocarriers, resulting in effective tumor growth sup-
pression. Nuclei-targeting systems have also been tested
throughtheuse ofaneasilyfabricatedyetentirelybiocom-
patible and inexpensive polysaccharide-functionalized
nanoscale lipid carrier, which triggers the intracellular
release of PS inside cancer cells and targets cell nucleus to
achieve a significantly enhanced photocytotoxicity. This
system may contribute to the development of a new
generation of PS carriers that fight against deep-seated
tumors and exhibit excellent photodynamic efficiency
under faint light irradiation (104).
Improving the pharmacokinetics of PS
Several PS for anticancer PDT demonstrate a strong
hydrophobic nature (34). Such is the case for various PS
that have been clinically approved. This hydrophobicity
presentspositiveandnegativeaspects.Thepositivepointis
the higher accumulation and retention of hydrophobic PS
in tumor cells (105, 106). This may be due to the fact that
hydrophobic PS (i.e. hypericin) associates with serum
lipoproteins, such as low density lipoproteins (LDL)
(107), which are avidly taken up by tumor cells (108). As
discussedbyDavidsandKleemann(30),thisfactisfurther
supported by a study conducted by Ho and colleagues
(109) showing that cholesterol serves as a key determinant
for the uptake of hypericin into cellular membranes.
On the other hand, hydrophobic PS readily aggregates
in water, hampering the administration of the drug
invivo,andalsodramaticallylosingphotodynamicactivity
(29, 31, 90). This may be a major limiting factor for PDT
potential clinical application. In this context, it is known
thatnanomaterialscanbeusedfordispersinghydrophobic
PS in biological media. For instance, in a study conducted
by Lima and collaborators (110), encapsulation of hyper-
icin in solid lipid nanoparticles improved photodynamic
efficiencyof this PS, showing a 30% increase in cell uptake
and a correlated improvement of 26% in cytotoxicity.
In another study, Muehlmann and collaborators (90)
showed that the photodynamic activity of aluminum-
phthalocyanine chloride (AlPc), a highly effective though
extremely hydrophobic phthalocyanine derivative, was sig-
nificantly improved in aqueous media by associating it
with poly(methyl vinyl ether-co-maleic anhydride) nano-
particles. When associated with these polymeric nanopar-
ticles, AlPc had its light-triggered singlet oxygen generation
capacity increased by 10-fold in aqueous medium com-
pared to its free form (90).
Exploring beyond the visible: UCNPs
Some researchers have explored optical properties of
nanomaterials in order to circumvent the problem of light
absorption by melanin in PDT (99, 111, 112). Particularly
interesting, a type of nanomaterial known as upconver-
sion nanoparticles participates in a non-linear optical
process that converts two or more low-energy pump
photons from the near-infrared (NIR) spectral region
(7001100 nm) to a higher-energy output photon with a
shorter wavelength. In simpler terms, UCNPs serve as
nanotransducers that convert deeply penetrating NIR
light, which does not have enough energy to promote the
triplet to singlet state conversion in molecular oxygen,
into visible light (VIS) (81). VIS light converted by the
UCNPs is then transferred to an appropriate PS with an
excitation band matching the emission of the UCNPs.
Upon excitation of UCNPs with NIR light, the ensuing
fluorescence resonance energy transfer (FRET) to the
attached PS produces cytotoxic reactive oxygen species
that react with surrounding molecules (39).
In recent years, UCNPs usually containing rare-earth
elements that exhibit upconversion properties have been
developed for applications in biological labeling, sensing,
andimaging (113).Idris andcollaborators (81) carried out
preclinical studies in which they tested the efficacy of
mesoporous-silicacoatedupconversionfluorescentnano-
particles, co-loaded with photosensitizers merocyanine
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first research group to test UCNP-based targeted PDT
in vivo. Tumor growth inhibition was observed in PDT
treated mice, suggesting the procedure as a platform
for future noninvasive deep-cancer therapy. The principle
behind UCNPs allows the application of NIR light in
PDT,permittinggreaterpenetrationdepthinmelanin-rich
tissues, in comparison to VIS light (99, 111, 112), since
light absorption by biomolecules is minimal in the NIR
region. To illustrate this point, a study showed, in bovine
muscle, that 37%of500to600-nm lightreachedadepthof
4 mm, while this same amount of 800-nm light reached an
8 mm depth in this same tissue (114, 115). Concerning the
production of
1O2, Wang et al. showed that the PS Ce6
alone,excitableby660-nmlight,didnotproduce
1O2when
irradiatedinporktissueatadepthof8mm;however,when
associated to 980-nm light absorbing UCNPs, Ce6 pro-
duced decent levels of
1O2 at the same depth (116). These
dataconfirmthatNIRlightpenetratesdeeperinbiological
tissues if compared with visible light. Other studies have
also demonstrated UCNPs efficiency in the treatment of
other types of cancer in in vitro and in vivo models,
highlighting the promise of UCNPs for multifunctional
cancer theranostics (39, 113, 117119).
Some drawbacks for UCNP-based PDT, however, have
yet to be properly addressed by future researchers, as
discussed elsewhere (120). These drawbacks include:
1) low brightness; 2) excitation wavelength of 980 nm,
commonly seen for most UCNPs, overlaps with the
absorption of light by water, thus may bring tissue
heating-related problems for UCNP-based PDT; and
3) biodegradability is quite low, requiring UCNPs to be
smaller than 10 nm in diameter.
Perspectives on the application of
nanotechnology and PDT for the
treatment of melanoma
As mentioned before, several types of nanomaterials have
already been used along with PDT for the treatment
of melanoma in in vitro and in vivo experimental models
(Table 1), obtaining promising results. However, when it
comes to completed clinical trials, these have focused
either on the use of PDT for melanoma treatment or on
the application of nanotechnology to improve treatment
for this type of skin cancer. Most PDT clinical trials have
focused on the treatment of choroidal melanoma and
have used ranibizumab along with PDT in phase II study
(NCT01251978); and indocyanine green (ICG) - based
PDT in phase IV trials (NCT01253759). Another study
combined the use of ranibizumab with ICG-based PDT
in phase III trial (NCT00680225). One other trial
involving the treatment of skin melanoma employed
verteporfin for patients with stage III and IV melanoma
(NCT00007969) (1).
Likewise, only a few trials have investigated nanomedi-
cine for melanoma so far, but in view of the amount of
preclinical work that is underway, it would be logical
to assume that the number of clinical studies is set to
dramatically increase in the next few years. Most of
these nanomedicine clinical trials researching melanoma
have explored the use of albumin-bound paclitaxel for
unresectable skin and uveal tumors, using one chemo-
therapeutic (NCT00738361; NCT00081042) or a combi-
nation with other drugs (clinical trials NCT00626405;
NCT00404235) (121). As mentioned before, it is known
that nano-based therapeutics offer distinct advantages
over conventional drug treatments in the sense that they
can provide multifunctional combinations of targeting
ability, diagnostic value, and therapeutic capacity, all in
one unique particle (Fig. 3). Baldelli and colleagues (1)
extensively explored this topic in their review article where
they present several studies, mainly preclinical, focused
on a variety of nanomaterials currently used to treat
melanoma and strategies to improve nanoencapsulation
and consequent delivery of common chemotherapeutics.
The next generation of nanoparticles will need to
address the challenge to successfully reach not only the
tumor cells themselves but also the different tissues and
organswhere metastases of late-stage tumors have spread.
In the case of melanoma, metastases are present in a
range of tissue types, and every tissue has its own unique
challenges for nanoparticle penetration (1). Thereafter,
it is possible that a promising solution to truly improve
the efficacy of melanoma theranostics involves the com-
bination of PDT and nanotechnology, perhaps through
the use of multifunctional UCNPs and targeted PDT
(39, 81, 113, 122). Moreover, the use of multimodal
therapies leading to synergistic effect has become a
promising approach to enhance anti-cancer therapy,
reduce undesirable systemic toxicity and side effects
(123). PDT along with magnetohyperthermia, photother-
mal therapy and electrochemotherapy using nanomater-
ials has also been studiedwith the perspective of achieving
enhanced therapeutic cancer treatments (123130). Mag-
netohyperthermia refers to a temperature rise caused by
energy dissipation in the form of heat from magnetic
nanoparticles that respond to an alternated frequency
magnetic field.Thistemperatureelevationinitiatesaseries
of subcellular events, rendering the cells to be susceptible
tovariousformsofdamageincludingapoptosis,leadingto
subsequent cell death (131, 132). Photothermal therapy is
a laser-based technique that involves optical absorbing
agents, such as gold nanostructures, carbon nanomater-
ials, various other inorganic and organic nanoparticles
with strong NIRabsorbance, to effectively convert photo-
energy into heat to kill cancer cells under light irradiation
(133). Electrochemotherapy combines electropulsation of
tumor cells (by local application of electric pulses) and the
administration of antineoplastic drugs such as cisplatin or
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relation to the application of these therapies for the
treatment of melanoma, since magnetohyperthermia is
not dependent on light, it may circumvent the problem of
pigmentation. Photothermal therapy is dependent on
light, but in this case NIR-light can be used, also avoiding
extensive absorption by melanin. Electrochemotherapy
enhances the penetration of chemotherapeutic drugs, and
may be useful for increasing the penetration of PS as well.
However, all of these therapeutic approaches still need to
be better understood and standardized in in vivo and
clinical studies. Future research should be oriented on this
typeofsynergisticeffects,alongwiththeuseofnanothera-
pies,in awaythatmelanomatreatment caninfact bemore
efficiently accomplished.
Conclusion
When it comes to the treatment of melanoma, the
outcomes of clinically available anticancer therapies are
still very poor. Moreover, over the last decades, these
therapies were not significantly improved. In face of this
scenery,itisnecessarytorethinkthestrategyanddesignof
new tools for melanomatreatment taking into account the
recent technological advances in the field of anticancer
therapy. On that ground, PDT has been experimentally
shown to strike cancer by different mechanisms, showing
to be a good candidate for the treatment of different types
of cancer. Although it has been clinically applied against a
number of different cancer types with an encouraging
therapeutic efficacy, its application against pigmented
melanoma remains a challenge. Nanotechnology offers
Fig. 3. An ideal multifunctional nanosystem for the treatment of melanoma using photodynamic therapy (PDT), hyperthermia,
site speciﬁc drug delivery, and targeting moieties. Photosensitizers and chemotherapeutics can be coupled or encapsulated to a
silica or polyacrylamide shell for simultaneous PDT/chemotherapeutic treatment with site speciﬁc drug delivery. Nanoparticles
can also be targeted to cells of interest or to tumor vasculature by surface-functionalization with targeting molecules. Contrast
enhancers can also be incorporated as diagnostic agents.
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therapies. This is also the case when nanostructures are
used for PDT against melanoma, as suggested by initial
works on this subject. Therefore, PDT based on nanotech
platforms may be a new approach for improving the
treatment of melanoma.
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